What happens if cancer cells lose both their mitochondrial energy supply and their glycolytic backup system? This question is central to a new study published in Research by researchers from Northwestern Polytechnical University and collaborating institutions. The work addresses a key limitation of cuproptosis-based cancer therapy: copper-dependent mitochondrial stress can kill cancer cells, but many tumors are metabolically flexible and rely heavily on aerobic glycolysis to survive mitochondrial damage. The study proposes a way to block both routes at once.

New parents receive little guidance on how to use a baby sling or carrier safely, according to new research.

The new analysis provides complementary patient-centred evidence, showing that the benefits of semaglutide may extend beyond traditional clinical outcomes to how patients feel and function in everyday life. The estimated treatment difference corresponded to approximately eight additional days per year spent in full health.

A pioneering clinical trial has successfully enabled two patients with end-stage kidney disease to receive previously improbable kidney transplants. These individuals were considered among the most difficult in the nation to match with a compatible donor kidney due to harmful antibodies they had developed (“sensitized”). Researchers at the University of Pennsylvania (Penn) used chimeric antigen receptor (CAR) T-cell therapy, originally developed at Penn for treatment of blood cancer, to significantly reduce the level of harmful immune antibodies in these two highly sensitized patients, making kidney transplantation possible after years of waiting. The study’s findings appear today in the New England Journal of Medicine.

NYU researchers developed the "Lily stent," a redesigned drain for gastric leaks after sleeve gastrectomy surgery. Unlike standard bile duct stents, its shape is optimized for stomach cavities, reducing slippage and repeat procedures.